SeaSpine study validates pushback of cellular bone matrix products

Alan Condon -   Print  |

Cells in cellular bone matrix products do not improve fusion or bone formation, according to results of a preclinical SeaSpine study published in The Journal of Bone and Joint Surgery.

"The class of cellular bone matrices has become ubiquitous in spinal surgery, yet there is no compelling data that the cells offer any clinical benefit to justify the high price point," Jeffrey Wang, MD, co-author of the publication and director of the USC Spine Center in Los Angeles, said in a Nov. 3 news release.

The study tested CBM products both with and without the cells to allow for only one variable.

Results showed no difference in performance with or without the cells. Researchers concluded that they had no positive effect.

Additionally, researchers found that SeaSpine's OsteoStrand Plus demineralized bone matrix product outperformed the tested CBMs in its ability to promote fusion.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers